Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Stem cell transplantation

Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1

References

  1. 1.

    Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhäuser M, Juliusson G, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9:579–90.

    CAS  Article  Google Scholar 

  2. 2.

    Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, De Witte T, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009;115:4715–26.

    Article  Google Scholar 

  3. 3.

    Döhner H, Estey E, Grimwade D, Amadori A, Applebaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

    Article  Google Scholar 

  4. 4.

    Freeman SD, Hills RK, Virgo P, Khan N, Couzens S, Dillon R, et al. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. J Clin Oncol. 2018;36:1486–97.

    CAS  Article  Google Scholar 

  5. 5.

    Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422–33.

    CAS  Article  Google Scholar 

  6. 6.

    Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: Time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol. 2016;34:329–36.

    Article  Google Scholar 

  7. 7.

    Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, et al. Measurable residual disease (MRD) monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132:1703–13.

    CAS  Article  Google Scholar 

  8. 8.

    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

    CAS  Article  Google Scholar 

  9. 9.

    Medeiros BC. Interpretation of clinical endpoints in trials of acute myeloid leukemia. Leuk Res. 2018;68:32–39.

    Article  Google Scholar 

Download references

Acknowledgements

We thank M. Robinson for thoughtful discussion and formatting support. We also acknowledge the work of Sandra Loaiza, head of operations at the John Goldman Stem Cell Facility and David Slade, data manager at Imperial College Healthcare NHS Trust. AJI is supported by a National Institute for Health Research (NIHR) Clinical Lectureship, and AJI and JFA acknowledges support from the NIHR and Imperial Biomedical Research Centre (BRC).

Author contributions

AJI, JP and RS conceived, designed, performed the research and wrote the manuscript. PW, SL, FF and DB collected and collated data, and AJI and RS performed statistical analysis. PCM, ENM and EYF performed MRD analysis. RP, DM, EO and JFA provided guidance on the research strategy. All authors reviewed and edited the manuscript.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jiří Pavlů.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Innes, A.J., Woolley, P., Szydlo, R.M. et al. Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality. Leukemia 34, 667–670 (2020). https://doi.org/10.1038/s41375-019-0572-z

Download citation

Search

Quick links